Schingles is expected to be released in the end of the year

Expected permission from the end of the year to the beginning of next year

97% superior efficacy over 50 years old, 51% in the case of Zostavax

GSK's Schingles, which boasts the highest efficacy among the existing shingles vaccines, is expected to receive product approval at the end of the year as soon as possible.

 

When Schingles is released in Korea, fierce competition is expected with Zostavax and Sky Zoster.

 

According to the pharmaceutical industry on the 21st, GSK applied for Schingles item approval from the MFDS in January and is currently undergoing review.

 

Approval is expected within the year, considering the period of time it normally takes for a permit review.

 

It is expected that it will be able to obtain a permit at the latest early next year.

 

Schingles was first approved in the United States in October 2017 and in Europe and Japan.

 

In the US, the market share reached 98% a year after the launch of Schingles.

 

Worldwide sales amounted to ￦1.1 trillion in 2018, ￦2.5 trillion in 2019, and ￦3 trillion in 2020.

 

The defense rate is stronger than other products.

 

In a clinical trial involving adults 50 years and older (ZOE-50), Schingles demonstrated a 97.2% ERA at 3.2 years of follow-up.

 

Those over 70 years old (ZOE-70) showed 89.8% efficacy after 3.7 years of follow-up.

 

The conventional vaccine, MSD's Zostavax, showed 51% protection in patients over 50 years of age.

 

It was 41% of those over 70 years old.

 

SK Bioscience's Sky Zoster has no known ERA figures.

 

With a non-inferiority test against Zostavax, it can be assumed that the ERA is similar.

 

Schingles is an inactivated vaccine, unlike the live attenuated vaccine Zostavax, and is particularly recommended for patients with weakened immunity.

 

Accordingly, the CDC recommended Schingles first over existing products as a shingles vaccine for adults over 50 years of age.

 

People who had previously been vaccinated with Zostavax also recommended Schingles re-vaccination.

 

Schingles has two doses and is a bit more expensive.

 

Zostavax and Sky Zoster are given a single dose, whereas Schingles requires two doses at intervals of 2 to 6 months.

 

The price is also expected to be higher than the two products.

 

Concerns over Schingles' supply shortages are reported to be largely resolved.

 

At the time of launch, there was a shortage of supply due to failure to keep up with demand.

 

Accordingly, GSK is continuously expanding its production capacity and increasing its supply.

 

Currently, the domestic shingles vaccine market includes Zostavax and Sky Zoster.

 

Originally, Zostavax was the only one, but with the launch of Sky Zoster in October 2017, it quickly eroded the market.

 

Market sales of Zostavax and Sky Zoster based on IQVIA last year were ￦43.2 billion and ￦29.1 billion, respectively.

 

Competition between the three products will be fierce from next year when Schingles sales are in full swing.